this result will also entitle the company to large amounts of non dilutive funding in the period ahead for this cardiovascular category. Aptoll recieved 6 million on their infarct results in non dilutive funding
Ann: Supplementary NYR-BI03 Study Confirm Strong Cardioprotection, page-3
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
29.0¢ |
Change
0.010(3.57%) |
Mkt cap ! $59.05M | |||
| Open | High | Low | Value | Volume |
| 28.5¢ | 29.5¢ | 28.5¢ | $5.149K | 17.92K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 9451 | 29.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.5¢ | 108848 | 2 |
View Market Depth
| Last trade - 10.15am 21/07/2025 (20 minute delay) ? |
| NYR (ASX) Chart |